Advanced practice nurses will increase their knowledge of the latest evidence for understanding pain management and opioids and apply that information to their practices using a patient centered approach to improve their outcomes. This newly updated course is designed to meet the FDA’s Opioid Analgesic REMS. CO*RE Case-Based Curriculum: CO*RE Case-Based Curriculum: Our case-based session delivers a real-world educational experience through a series of cases and supporting content mapped to segments of the FDA Blueprint. This allows faculty to teach application of concepts, fostering an engaging approach to pain management education.
By the end of this session, the learner will be able to recognize the origin(s) and types of pain as they relate to pain management and opioid use disorder (OUD), fully assess persons experiencing pain, including risk for OUD, develop safe and effective pain management plans using nonpharmacologic and pharmacologic (non-opioid or opioid) options, and partner with patients to reduce risks when taking opioid therapy. Supplemental education also available includes modules on telehealth, addressing cannabis, fentanyl, stigma, health inequities/social determinants, and surgical education; a pocket-ready guide; a podcast series; and numerous brief teaching videos.
This program meets many states’ requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blueprint”), issued by the U.S. Food & Drug Administration in October 2023. As of June 27, 2023, DEA registrants are to have completed a total of at least 8 hours of training on opioid or other substance use disorders.
The curriculum was developed by the Collaborative for REMS Education (CO*RE) http://core-rems.org and is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC).
This course meets the criteria outlined by Substance Abuse and Mental Health Services Administration (SAMHSA) to count toward DEA required training. The Access and Training Expansion (MATE) Act requires new or renewing Drug Enforcement Agency (DEA) registrants, as of June 27, 2023, to have completed a total of at least eight hours of training on opioid or other substance use disorders.
Contact Information: Presented by Nurse Practitioner Healthcare Foundation, a member of the Collaborative on REMS Education (CO*RE), ten interdisciplinary organizations working together to improve pain management and prevent adverse outcomes, including AAFP, AANP, AAPA, AAHPM, AOA, ASAM, CAFP, IPMA, NPHF & AAOS. For more information, please contact NPHF or visit www.core-rems.org
CE for Nurses/Nurse Practitioners: This educational activity will be submitted to the American Association of Nurse Practitioners® for approval of up to 2.0 contact hours of accredited education.
This activity was planned in accordance with AANP Accreditation Standards and Policies.
This learning activity is presented in partnership with the CO*RE Collaborative.
Criteria for Awarding Contact Hours: This course provides 2.0 contact hours including 2.0 pharmacology hours. Criteria for awarding the contact hour includes completion of the course, evaluation, and post-test.
Accredited Provider Disclosure: As a provider dedicated to independent education and accredited by the AANP, NPHF must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All individuals with the ability to influence the content of this educational activity reported the following: none of the advisors, reviewers or planners for this educational activity have relevant financial relationships with ineligible companies to disclose.
Faculty Disclosure: Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, Glaxo Smith Kline, consultant, honoraria and consulting fee, pain/osteoarthritis; AXSOME, speaker bureau, honoraria, depression and migraines; AbbVie and Pfizer, speaker bureau and advisory board, honoraria and consulting fee, migraines.
Commercial Support: This educational activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration (FDA).